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Interleukin-la (IL-la) and tumor necrosis factor-a 
(TNF-a) induce a motogenic response in a number of benign 
and malignant cells. We examined the chemokinetic effects 
of these cytokines on the cell migration of four melanoma 
cell lines on fibronectin using modified Boyden chambers 
and video-time lapse analysis. Flow cytometry analysis of 
IL-l receptors, TNF receptors, and shifts in PI integrin ex-
pression were correlated with the effects of these cytokines 
on cell migration on fibronectin. The four melanoma cell 
lines exhibited heterogeneous expression of types I and II 
IL-l receptors as well as p60 TNF receptors. Scant p80 TNF 
receptor expression was detected on only one cell line. Three 
of four melanoma cell lines demonstrated type I IL-l recep-
tors by Western blotting. IL-la and TNF-a induced hetero-
geneous modulation of PI integrin expression in the four 
M alignant cells, like many benign cell types during embryogenesis, exhibit a capacity for cell migra-tion. Regulation of cell motility is complex, and involves an interplay of cytoskeletal proteins, ad-hesion molecules, ion fluxes, and cell-surface re-
ceptors that relay signals to set the cell in motion. Several cytokines 
that have potent motogenic properties have recently been identified 
[1] . Lymphocytes, fibroblasts, and endothelial or tumor cell produc-
tion of cytokines may have dramatic effects on the motility of ma-
lignant cells, providing the malignant cells express the appropriate 
receptors. Exactly how cytokines signal motility is unclear; how-
ever, recent findings indicate that interleukin (IL)-1P, tumor necro-
sis factor (TNF)-a, and transforming growth factor (TGF)-P are 
able to modulate integrin expression on a variety of cells [2-5]' 
Integrins are a family ofheterodimeric transmembrane receptors 
composed of an a and P subunit and are believed to be important 
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melanoma cell lines tested; downward shift of the a 2 , a3 , a4 , 
and PI integrin subunits was detected among three of the 
melanoma cell lines as were upward shifts of the a 4 , as, and 
a6 integrin subunits among three of the melanoma cell lines. 
IL-la and TNF-a induced enhanced migration on fibronec-
tin in one of the melanoma cell lines and were related to an 
upward shift in the a 4 and as integrin subunit expression. 
Taken together, the findings indicate that expression of a 
particular receptor for IL-l or TNF does not necessarily sig-
nal a motogenic response in melanoma cells, but induces 
heterogeneous shifts in PI integrin expression. However, up-
regulation in a4 and as integrin subunits appears to relate to 
enhanced migration on fibronectin. Key words: migration/ 
tumor necrosis factor/interleukin 1/integrin. ] Invest Dermatol 
102:898-905, 1994 
molecules in cell adhesion and motility in normal and malignant 
cells [6]. Tumor cell invasion requires attachment to and migration 
through a number of extracellular matrix molecules [7], and inte-
grins belonging to the very late antigen (VLA) family, those with a 
common P! subunit, are known to exhibit changes in levels of ex-
pression on neoplastic transformation [B,9] . Cell transformation or 
exposure to certain cytokines have in common an alteration in cell 
behavior on extracellular matrix (ECM) proteins that is the result of 
shifts in integrin expression [2,4,9,10]. 
The expression of P! integrins in human melanoma is heteroge-
neous [11 J and the pattern of expression dictates differential adhe-
sion [4,12] or migration behavior on specific extracellular matrix 
molecules [13] . Exposure of melanoma cells to TNF-a has recently 
been reported to result in their increased adhesion to fibronectin [4]. 
Specifically, upregulation of the asP! integrin was reported. This 
integrin, along with a 4P! and a.jJ!, is known to bind the extracellu-
lar matrix protein fibronectin [14 -17]. 
We hypothesize that a cytokine-induced shift in asP! expression 
may relate to motogenic properties of certain cytokines. Therefore, 
we tested the effect ofTNF-a as well as another known motogenic 
cytokine, IL-1a, on the migration of a number of melanoma cell 
lines using micropore transmembrane and video time-lapse migra-
tion assays. Heterogeneity of response among the cell lines could 
relate to differential expression of cytokine receptors. Therefore, we 
used indirect immunofluorescence and flow cytometry utilizing 
monoclonal antibodies against the two recently described types of 
TNF receptors-p60 and pBO TNF-R [1B-21]-and the two 
types ofIL-l receptors-types I and II IL-1R [22,23]. In addition, 
Western blotting with type I IL-l R was performed on the four cell 
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Figure 1. Representative video time-lapse migration assay of the four mel-
anOIna cell lines on fibronectin following exposure to TNF-a and IL-1a. 
Whereas the PM-WK, RPM-EP, and MM-AN cell lines exhibit no signifi-
cant increase in motility, a significant increase in mean migration rate of the 
MM-RU cell line is observed with both TNF-a ("p < 0.005) and IL-1a 
incubation (' p < 0.001). 
lines tested. Finally, TNF-a- and IL-la-treated melanoma cell 
lines were examined by quantitative flow cytometry to determine 
whether cytokine-induced motogenic effects related to specific 
shifts in integrin expression. 
MATERIALS AND METHODS 
Melanoma Cell Lines and Culture Conditions The primary mela-
noma cell line PM-WK, isolated from the radial growth phase, the recurrent 
melanoma cell line, RPM-EP, from the vertical growth phase, and the 
metastatic cell lines, MM-AN and MM-RU, from lymph nodes. were iso-
lated in permanent culture and maintained using standard culture media 
with 2% fetal bovine serum and 8% newborn bovine serum as previously 
described [24]. 
Extracellular-Matrix Coating Procedure Microcover glasses used in 
the cell migration assay (see below) were coated with fibronectin (FN) or 
larninin (LN) (Collaborative Research Inc .• Bedford. MA) diluted in phos-
phate-buffered saline (PBS) to 10,ug/ml for 1 hat 37'C following estab-
lished techniques [25]. Overnight coating with 20 mg/ml heat-denatured 
bovine serum albumin (dB SA) at 4 'C was performed to block nonspecific 
binding sites. The upper and bottom side of the micro pore membranes in 
modified Boyden chambers (see below) were similarly coated with FN and 
dBSA. Throughont the paper and figures. FN/dBSA-coated snbstrates are 
terrned FN substrates. 
cytokines and Monoclonal Antibodies Human recombinant IL-la 
was a generous gift of Hoffmann-LaRoche Inc. (Nutley, NJ) and human 
TNF-a (catalogue number 40066) was purchased from Collaborative Bio-
medical Products (Bedford, MA). The mouse anti-human type I IL-IR 
(Catalogue number 1592-01). type II IL-IR (Catalogue number 1994-01), 
and anti-human p60 TNF-R (Catalogue number 1995-01) and rat anti-
human p80 TNF-R (Catalogue number 1888-01) monoclonal antibodies 
were purchased from Genzyme (Cambridge. MA). The fluorescein-conju-
gated goat anti-rat (Catalogue number 311-1202) was purchased from 
Rockland Inc. (Gilbertsville, PAl and the fluorescein goat anti-mouse (Cata-
logue number 55493-12110081) from Cappel Laboratories (Durham. NC). 
The monoclonal antibody (MoAb) against the extracellular domain of the 
common PI subunit (AIIB2) of the VLA family and function blocking MoAb 
against the as integrin subunit (BIIG2) were a kind gift of Dr. Caroline H. 
Damsky (University of California, San Francisco. CAl. Dr. Martin Hemler 
(Dana-Farber Cancer Institute, Boston. MA) kindly provided the MoAb to 
the a l subunit (Ts2/7), which binds to the extracellular domain but does not 
functionally block cell adhesion, and the rat MoAb to the a6 subunit (GoH3) 
was a generous gift of Dr. Arnoud Sonnenberg (Central Laboratory of The 
Netherlands, Amsterdam, The Netherlands). The function-blocking 
MoAbs against the a4 (P4G9), a2 (PIE6). and a3 (PIB5) integrin subunits 
were purchased from Telios Pharmaceuticals. Inc. (San Diego. CAl. Positive 
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Figure 2. Representative modified Boyden chamber transmembrane mi-
gration assay of the four melanoma cell lines on double-sided fibronectin-
coated micropore filters after exposure to TNF-a and IL-1a. No significant 
effects are seen with either cytokines on the migration of the PM-WK. 
RPM-EP. or MM-AN cell lines; however, both TNF-a and IL-la signifi-
cantly enhance the transmembrane migration of MM-RU melanoma cells 
('p < 0.001). 
control MoAb anti-human leukocyte antigen (HLA) class I (W6/32) was 
obtained from American Type Culture Collection. Negative control MoAb 
included an anti-Fe receptor antibody [26], fluorescein-conjugated anti-
mouse (or anti-rat) immunoglobulin (Ig)G alone [27], Fe fragment (Rock-
land Inc.), or unrelated mouse IgG isotype-matched fluorescein-conjugated 
antibodies (Becton-Dickinson, Mountain View, CAl. 
Transmembrane Cell Migration Through Double-Sided Fibronec-
tin-Coated Micropore Membranes Both sides of the modified Boyden 
chamber po~ycarbonate membranes (Transwell 24, 8-,um pore, 3422; Co-
star, Cambndge, MA) were coated and washed three times with PBS as 
described above. Cells of each melanoma cell line culture were added to each 
upper chamber unit of the transwell plate at 1 X 10s cells and cultured for 
24-48 h with or without IL-1a (1000 U/ml) or TNF-a (5 ng/ml; 100 
U/ml). Each membrane was then washed with PBS. fixed for 10 min inl0% 
formalin. and incubated for 5 min with 0.5% Triton X-I00. After cotton 
swab removal of upper chamber melanoma cells. the cells on the bottom side 
were stained with Gill's hematoxylin. All membranes were analyzed with an 
Image analYSIS system (Microcomp. Southern Micro, Atlanta. GA), which 
was used to obtain densitometry readings of four different 7-mm2 areas 
mcorporatmg nearly the entire membrane, using the 2 X objective. Stained 
~ells r~du~e pixel intensity; therefore. the reciprocal of the integrated pixel 
mtenslty IS proporti.onal to the number of migrated cells. Controls versus 
cytokme-treated urnts were analyzed using the Student t test. 
Video Time-Lapse Cell Migration Assay Subconfluent cultures of the 
melanoma ce!l lines were obtained in suspension after trypsinization or 
ethylenedlanune tetraacetic acid (EDT A) treatment. Approximately 4 X 
!O' cell.s were. plated in the center of each FN-coated coverslip and incubated 
m medIUm Without cytokine or medium containing 1000 U/ml IL-la or 5 
ng/ml (100 U/ml) TNF-a. The concentrations used were derived from 
titra~ion assays that elicited maximal motility response. Cell migration was 
studied during similar 3-h intervals after 24. 48, and 72 h of control or 
cytokine incubation using a Nikon Diaphot inverted microscope with a lO X 
phase-contrast objective and attached mcubator as described previously 
[24,.26]. Briefly, the cells were maintained at 37°C in a 5% CO2/95% air 
e~IVuonment and the cell migration recorded using a Dage-MTI 65DX 
Video camera and a Hitachi TLC1550 time-lapse video cassette recorder. For 
each experimental condition. migration of at least 20 cells was analyzed. 
Data were analyzed as described above. 
Immunofluorescent Staining for Types I and II IL-1Rs and p60 and 
p80 TNF-Rs Melanoma cells were plated in eight-well tissue tek 
chambers (Nunc. Napervi lle. IL). Following 24-h incubation. cells were 
fixed for 2 min with 4% paraformaldehyde in PBS. To block nonspecific 
binding sites. cells were incubated for 30 min at 37'C with 50 tl12% BSA in 
PBS, briefly rinsed with PBS, and incubated for 30 min at 37 ' C with 50,u1 of 
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Figure 3. Indirect immunofluorescent staining of attached melanoma cells 
for the pBO TNF-R showing little or no detectable staining on the PM-WK 
(B) , RPM-EP (D), and MM-AN ( F ) cell lines as compared to controls 
(A,C,B). The MM-RU cell line exhibits detectable staining (H) compared 
to control (G). Bar, 50 pm. 
the primary antibody against the specific cytokine receptor (see Monoclol/a! 
Alltibody section), diluted 1 : 50 in 0.5% BSA in PBS. Preparations were then 
incubated for 30 min at 37 °C with 50 III of a 1 : 40 dilution in 0.5% BSA in 
PBS of the appropriate secondary fluorescein-labeled antibody (see MOl/oe/o-
110/ Alltibody section) following three washings in PBS. Negative controls 
were incubated with the secondary fluorescein-labeled antibody alone or 
were previously incubated with an unrelated IgG isorype antibody. Finally 
the cells were embedded in mounting medium, placed under the 20 X 
objective on a Nikon epifluorescent microscope (microphot), and photo-
graphed with a fixed exposure time using 400 TMAX Kodak film. 
Flow Cytometry: Types I and U IL-lRs and p60 and pSO TNF-Rs 
Melanoma cells plated in T25 Corning tissue culture flasks (catalog number 
25106, Falcon, Fischer Scientific) were cultured to subconfluence for 24, 4B, 
and 72 h in regular medium or medium containing 1000 U/ml IL-lfr or 5 
ng/ml (100 U/ml) TNF-a at 37°C in a 95% air-50/o CO2 atmosphere. After 
trypsinization or EDTA treatment, cells were washed in PBS, incubated for 
30 min with fluorescein-labeled goat-anti-rat or anti-mouse antibody (t : 40 
dilution), and then incubated for 30 min at 4 ° C with MoAb against the rat 
anti-human TNF receptor pBO antibody or one of the mouse anti-human 
antibodies against either the p60 TNF-R, the rype I IL-l R, or the rype II 
IL-R. Negative controls included all cells pre incubated with the human IgG 
Fc fragment, incubation with the fluorescein isothiocyanate (FITC)-anti-
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mouse/anti-rat IgG alone, or incubation with the appropriate rat or mouse 
IgG isorype-FITC antibodies. Positive controls included incubation of nor-
mal peripheral blood lymphocytes and monocytes isolated by Ficol gradient 
separation with all four anti-receptor MoAbs tested. Samples were analyzed 
with a Becton-Dickinson Facscan cytometer. 
Western Blot Analysis of Type I IL-lRs in Four Melanoma Cell 
Lines Melanoma cel ls were detached by scraping into a 15-ml tube and 
spun at 1500 X g for 5 min. Human T-lymphocytes, a kind gift of James 
Kurnick, were cultured in suspension and pelleted at 1500 X g. The cel ls 
were lysed in 0.5 ml RIPA buffer (150 mM NaCl, 1.0% Nonidet P-40, 0.5% 
deoxycholic acid, 0.1 % sodium dodecyl sulfate [SDS), 50 mM TRIS; pH 
B.O). Cell lysate were added to sample buffer and loaded onto SDS 4-12% 
polyacrylamide gradient gels. Electroclution onto nitrocellulose filters was 
performed in 50 mM TRIS, 380 rnM glycine, 20% methanol, and 0.1 % 
SDS. The filter was removed and dried, incubated for 30 min in 2.5% skim 
milk to block nonspecific binding sites, and then incubated for 2 h with the 
MoAb diluted in 0.5% skim milk at a concentration of20 pg/ml. Following 
two washes in TRIS-buffered saline (TBS) with 0.1 % Triton X-tOO and one 
in TBS, each for 15 min, the filter was incubated with the secondary anti-
body and developed using avidin-biotin peroxidase (ABC kit; Vector Labo-
ratories, Burlingame, CAl. 
Flow CytoDlctric Evaluation of Expression of /1. Integrins After 
IL-la or TNF-<r Incubation After plating for 24 h, melanoma cell cul-
tures were maintained for 24, 4B, or 72 h in regular medium or medium 
containing 5 ng/ml (100 U/ml) TNF-a or 1000 U/ml IL-la containing 
medium. Cells were detached using trypsin/EDTA or EDTA alone and 
incubated for 30 min at 4°C with the 40 Ilg/ml Fe fragment, then for 30 min 
with MoAb against one of the p, integrin subUl1its (fr" fr2' a3 , a. from 
ascites fluid in a 1 : 500 dilution in modified Eagle's medium [MEM] and a 
1: 5 dilution in MEM for as, fr6' and p, from hybridoma-conditioned me-
dium). Following PBS washing, cells were incnbated with the appropriate 
fluorescein-labeled goat- anti-mouse or goat-anti-rat antibody (1 : 40 dilu-
tion) or the appropriate control fluorescein-labeled isorype antibodies for 30 
min and analyzed as outlined above. 
Mean fluorescence intensiry values give only part of the necessary infor-
mation to evaluate shifts in expression of surface molecules and do not 
convey the peak, shape, or other parameters of the fluorescence histograms. 
Therefore, shifts in integrin subunit expression following treatment with 
the cytokines were compared to controls (cytokine untreated) by the Kol-
mogorov-Smirnov two-sample statistical analysis of histograms [28). We 
consistently obtained 10,000 counts for each experimental condition and 
each subunit or receptor. To reject the null hypothesis that two cell popula-
tions are the same at the 99.5% confidence level (a = 0.001), calculated D 
values must be larger than the D(n) critical value (Dc", = 0.03 for n = 
10,000 events) [2B] . Furthermore, the greater the calculated D value com-
pared to the Dm" the histograms show greater shifts between the two 
populations. We chose a range of arbitrary D values to categorize the detect-
able shifts in the histograms as follows: absent or minimal shift if D is less 
than 0.15; slight upward shift or slight downward shift for D between 0.15 
and 0.25; and marked upward shift or marked downward shift for D greater 
than 0.25. 
RESULTS 
Effect ofIL-la or TNF-a on Motility of Melanoma Cells on 
FN-Coated Substrates After 48 h exposure to IL-la orTNF-a, 
the mean migration rates on FN of the four cell lines were compared 
to cytokine nonexposed cells using the video time-lapse migration 
system. Three of the melanoma celJ lines (PM-WK, RPM-EP, and 
MM-AN) did not show a significant increase or decrease in mean 
migration rate, which ranged from 4 to 14 JLmjh (Fig 1). In con-
trast, the eel/line that had a high baseline migration rate (MM-RU; 
18 JLmjh) exhibited a significant increase in mean migration rate in 
response to TNF-a (p < 0.005) and IL-Ia (p < 0.001). This re-
sponse of the MM-RU cell line was substrate specific; cytokine-
treated cells that were plated on LN showed no significant increase 
in migration rate compared to controls. 
Similar findings were observed using the micropore transmem-
brane assay system (Fig 2). After 48 h, densitometry readings of 
stained cells, proportional to the number of stained transmembrane 
migrated cells, showed that TNF-a and IL-la had no effect on the 
migration of the same three melanoma cell lines that did not re-
spond in the video time-lapse assay. In contrast, the MM-RU cell 
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line exhibited a significant increase in transmembrane migration 
over 48 h in response to TNF-a (p < 0.001) and IL-la (p < 
0.001), similar to the video time-lapse assay results. 
Immunofluorescent Staining of Types I and II IL-1Rs and 
p60 and p80 TNF-Rs in Attached Melanoma Cell Lines In-
direct immunofluorescent staining of attached melanoma cell lines 
revealed heterogeneous expression of IL-l and TNF receptors. 
Whereas no receptors could be detected on one cell line (PM-WK; 
see representative photomicrographs in Fig. 3), the other lines ex-
hibited differential expression of types I and II IL-1Rs and p60 and 
p80 TNF-Rs. The cell line RPM-EP exhibited slight staining for 
the type I IL-IR, strong staining for the type II IL-IR, slight stain-
ing for the p60 TNF-R, and was also negative for the p80 TNF-R 
(Fig 3D). The cell line MM-AN exhibited slight staining for the 
type I IL-IR, mild staining for the type II 1L-1R and p60 TNF-R, 
and negative staining for the p80 TNF-R (Fig 3P). Finally, the 
MM-RU cell line, which was the only cell line that demonstrated a 
• motility response to IL-1a and TNF-a, exhibited slight type I 
IL-l R staining, moderate type II IL-l Rand p60 TNF-R staining, 
and slight p80 TNF-R staining (Fig 3H). To better quantify the 
expression of these receptors, we performed flow cytometry as out-
lined below. 
Flow Cytometric Analysis of Types I and II IL-lRs and p60 
and p80 TNF-Rs To verify the immunofluorescent findings on 
the fixed, attached cells, we performed quantitative flow cytometric 
analysis of all four cell lines following indirect immunolabeling of 
t~e four cy.tokine receptors (Fig 4). Cells that were detached by 
either trypsmjEDT A or EDT A alone gave similar results to the data 
on the attached fixed cells outlined above. In the PM-WK cell line, 
types I and 1.1 IL-1 Rand p80 TNF-R were not detected; however, a 
low expressIOn of p60 TNF-R was observed. In the RPM-EP line, 
the type I IL-1R and p60 TNF-R exhibited low expression whereas 
~pe ~I IL-.1R ~as highly expressed. No detectable p80 TNF-R was 
Ident1fie~ m this ~elliine. This pattern of expression compared well 
with the mdlre~t Immlll1ofluorescent staining of attached cells. The 
MM-.AN cellime exhibited a pattern different from the RPM-EP 
~ell lme, and also exhibited expression of receptors similar to the 
unmunofluorescent staining pattern of the attached cells. The types 
I and II IL-1Rs and p60 TNF-R exhibited low expression, whereas 
no p80 TNF-R was detected. Finally, MM-RU exhibited low to 
moderate expression of types I and II IL-lR and p60 TNF-R and 
low but detectable p80 TNF-R. 
. The expressions of these cytokine receptors in the melanoma cell 
lmes were ~onfirmed using peripheral blood lymphocytes and mon-
ocytes, which served as positive controls. All four cytokine recep-
tors were detected on these positive controls, with mean fluores-
cence values rangin~ from relatively low expression of p80 TNF-R 
to moderate expressIOn of type I IL-l R on lymphocytes (similar to 
that detected on the MM-RU cell line) and high expression of the 
P?O TNF-R to very high expression of type II IL-IR on monocytes 
(sumlar to that detected on the RPM-EP cell line). 
To study the kinetics of receptor expression following addition of 
IL-l or TNF-a, flow cytometry was performed for each of the four 
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Figure 5. Western blot of melanoma cell lines (Ialles 1-4) and cultured T 
lymphocytes (lanes 5,6) with monoclonal antibody against the type IIL-IR 
receptor. Bands are identified at 80-85 kDa in RPM-EP (Iallc 2), MM-AN 
(Ialle 3), and MM-RU (lane 4) and co-migrate with bands in the T-Iympho-
cyte lysates (lanes 5,6) . No band is detected in the PM-WKccllline (lane 1). 
receptors following exposure of the cells to these cytokines after 24, 
48, and 72 h. Compared to cytokine-untreated control cells after 24, 
48, and 72 h, a slight downregulation of the type I IL-IR was 
detected at 24 h and was sustained during exposure to IL-l. How-
ever, no detectable shifts of the type II IL-IR, p60 TNF-R, or p80 
TNF-R were observed with this cytokine. TNF had no effect on the 
expression of all four receptors over the 3-d time course studied. 
Detection of Type I IL-1R in Melanoma Cells by Western 
Immunoblot To confirm that the low to moderate expression of 
type I IL-IR detected by flow cytometry correlated with the actual 
receptor as characterized by Western blotting techniques, we char-
acterized the expression of type I IL-IR on the four melanoma cell 
lines using cultured T lymphocytes as a positive control (Fig 5) . We 
did not detect type I IL-l R in the cell lysate of one of the melanoma 
cell lines (PM-WK; Fig 5, lane 1); however, three of the melanoma 
cell lines demonstrated a band at 80-85 kilodaltons (kDa) (Fig 5, 
lanes 2-4). This band co-migrated with a prominent band detected 
in the T-Iymphocyte lysate (5 X dilution lysate, Fig 5, lane 5; 1 X 
lysate, Fig 5, lane 6). These findings correlated with the flow cy-
tometry detection of this receptor in three of the four cell lines. 
VLA-Integrin Expression Following TNF-a and IL-la 
Treatment Following TNF-a or IL-la incubation we examined 
VLA-integrin subunit expression in the four cell lines using flow 
cytometry. We hypothesized that shifts in integrin subunits known 
to bind FN could account for the difference in melanoma cell mi-
gration. Figure 6 is a composite of histograms illustrating shifts in 
a3 , (l'4' and (l's integrin subunits in the four cell lines following 
TNF-(l' or IL-l(l' incubation. The thick lined peaks represent con-
trol fluorescence with the secondary antibody alone; the fine lines 
represent the histograms following TNF-(l' or IL-l(l' incubation. 
TNF-(l' or IL-l(l' induced a downward shift in the (l'3 subunit in the 
PM-WK cell line. In contrast, TNF-(l' had no effect on integrin 
expression in the RPM-EP and MM-AN cell lines, whereas IL-la 
induced a marked downward shift of the (l'4 subunit in RPM-EP and 
a3 in MM-AN. On the other hand, MM-RU was the only cell line 
with marked upward shifts in integrin subunits involved in FN 
binding. Both TNF-a and IL-1(l' induced marked upward shifts in 
a4 and (l's subunit expression. Table I summarizes the heteroge-
neous effects ofTNF-a or IL-l(l' on all the VLA integrin subunits in 
the four melanoma cell lines. Only a few other integrin subunits 
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demonstrated slight or marked shifts in the melanoma cell lines, and 
included a marked upward shift in the (l'1 subunit induced by IL-1(l' 
in RPM-EP, a marked downward shift in the a3 subunit in MM-
AN, and a marked upward shift of the (l'6 subunit in MM-RU in-
duced by IL-1(l'. The latter two shifts are confirmed by a concomi-
tant marked downward shift of the PI subunit in the RPM-EP cell 
line and marked upward shift in the PI subunit in the MM-RU cell 
line following treatment with only IL-l but not TNF-(l'. Interest-
ingly, the marked upward shift in the a l subunit and the downward 
shifts of (l'4 and a6 subunits induced by IL- l(l' in RPM-EP have the 
effect of canceling each other out and resulting in no detectable shift 
in the PI subunit expression. 
To study the kinetics of integrin expression following the addi-
tion of IL-1 or TNF-(l', flow cytometry was repeated on each of the 
four cell lines after 24, 48, and 72 hand cytokine-treated cells were 
compared to untreated cells over the same time period. We con-
firmed in the MM-RU cell line that at 24 and 48 h the (l'4 and (l's 
subunits demonstrated an upward shift in expression similar to that 
observed at 72 h with IL-l or TNF-a. Furthermore, the RPM-EP 
cell line showed a similar downshift in expression of only the (l'4 
subunit with IL-1 , but not TNF-(l', after 24 h. The other two cell 
lines showed no detectable shifts in these integrin subunits follow-
ing exposure to IL-l or TNF-(l' over the time course studied. 
To address whether increased a4PI or (l'sPl relates to enhanced 
motility, we performed a series of experiments using function-
blocking MoAbs against the (l'4 or as subunit. We found that en-
hanced motility on FN in the time-lapse video image analysis sys-
tem induced by TNF-(l' (19 ± 8.0 ,urn/h) could be inhibited 
significantly by 10 - 20 ,ug/ ml of the function-blocking anti-(l'4 sub-
unit (9.5 ± 7.5 ,um/h; p < 0.001) or the function-blocking anti-(l's 
subunit (11 ± 6.5 ,um/h; p < 0.001) . Likewise, the IL-1(l'-
enhanced motility (21 ± 4.0,um/h) could be inhibited significantly 
by the function-b locking anti-(l'4 (6.0 ± 4.0 ,um/h; p < 0.001) or 
anti-(l's (7.5 ± 4.5 ,um/h; p < 0.001) MoAbs. 
DISCUSSION 
The production of cytokines by lymphocytes, macrophages, and 
other cells is integral to the cellular immune response for control-
ling the growth or dissemination of tumor cells [29,30]. Certain 
cytokines may induce alterations of cell-surface molecules on tumor 
cells. This may playa key role in metastasis, as in the expression of 
growth receptors and cell adhesion molecules that regulate cell 
migration [6,7,31] . Melanoma cells are extraordinarily pleiotro-
phic, and the expression of receptors for cytokines that induce cell 
migration may select malignant cells that undergo dissemination. 
Tumor cells may mimic lymphoid cells in that they express certain 
adhesion molecules to permit trafficking into distant tissue sites. 
Cytokine-activated endothelial cells express cell adhesion molecule 
(VCAM)-l (also named INCAM-Il0) [32], which binds to the (l'4 
subunit (VLA-4) . Some melanoma-endothelial interactions use the 
identical adhesion receptors to bind to endothelium as do the lym-
phocytic cells [33,34] . IL-1 increases melanoma metastasis in nude 
mice [35], and this may be due to enhancement of certain adhesion 
molecules or cytokine receptors. Indeed, certain cytokines have 
been able to induce modulation of integrin molecules on normal and 
malignant cells [2- 5]. The shifts in integrin expression are largely 
dependent on TNF-(l' and IL-1, and these shifts have been found to 
coincide with altered phenotypic adhesive behavior to FN [2,4] . 
We addressed a number of questions regarding the role ofIL-1(l' and 
TNF-a on migration of a number of established cell lines. These 
cell lines show marked differential-intrinsic migration rates [24] 
and exhibit heterogeneous integrin expression [13,26], as reported 
in other melanoma cell lines [11,12]. First, we asked whether IL-1a 
or TNF-(l' are motogenic for these melanoma cell lines. Second, we 
examined whether IL-1 or TNF receptors could be related to be-
havioral responses to these cytokines. Third, does IL-1(l' or TNF-(l' 
induce shifts in integrin expression? And finally, does this relate to 
alterations in motility? 
We found that the melanoma cell line tested had differential 
migration responses afer IL-l(l' or TNF-(l' incubation, using the two 
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log Fluorescence Intensity 
Figure 6. R:epresentative experiment showi~g a?, a., and as .integrin subunit expression before. and af~er treatment with IL-la (lift fa.llels) orTNF-a (righ! 
panels). Ordmate IS relative cell number. Tlllck litle, control, mcubatlon m regular medIUm; tlllll litle, mcubatlon m medium contammg cytokme. 
different assays. These findings are in accordance with data showing 
that IL-la or TNF-a are motogenic in a variety of malignant cells 
[1,36 - 38]. This response was most likely via the IL-1Rs or TNF-
Rs, therefore we characterized the IL-1Rs and TNF-Rs in all the 
melanoma cell lines. There are at least two types of IL-l receptors, 
the type I (80-90 kDa) [22] and type II (60 - 68 kDa) [23] receptors. 
These two types of IL-l Rs have been identified in a variety of cell 
types. We report the presence of a heterogeneous pattern of these 
receptors on a number of melanoma cell lines tested. The type I 
IL-1R was detected in the majority of the melanoma cell lines 
tested, using flow cytometry, immunofluorescence, and Western 
blotting. The low fluorescence intensity on the melanoma cells for 
the type I IL-l Rs suggests that relatively few receptors are expressed 
compared to the type II IL-lRs on the RPM-EP cell line. The 
presence of detectable type I IL-IR alone did not correlate to the 
IL- la-induced enhanced migration. For example, the RPM-EP 
Table I. Summary of Cytokine Effects on PI lntegrin Expression (Flow Cytometry Analysis Showing Mean Fluorescence Intensity 
Values of the Four Melanoma Cell Lines Tested)-
a, a2 a) a. as a6 p, 
PM-WK 
Control 9.04 5.74 18.01 5.50 17.81 14.92 48.90 
+TNF-a 7.87 (4.93) (15.25) 4.86 16.64 13.50 42.29 
+ IL-la 7.40 (4.19) (16.91) 5.52 17.20 13.51 45.88 
RPM-EP 
Control 30.64 45.83 55.19 11.57 9.97 17.13 97.82 
+TNF-a 22.22 39.63 56.20 13.19 9.60 14.49 96.08 
+ IL-la 43.32 40.38 62.85 (8.45) 11.08 (12.63) 96.40 
MM-AN 
Control 25.24 14.54 31.15 8.06 7.45 11.52 74.20 
+TNF-O' 24.13 17.24 29.40 5.06 6.61 12.35 69.27 
+IL-la 25.30 15.53 (24.18) 6.59 6.88 10.92 (53.78) 
MM-RU 
Control 2.39 10.53 3.07 14.97 6.42 4.88 49.93 
+TNF-a 2.39 10.65 2.85 29.72 9.96 7. 18 53.1 2 
+ IL-10' 2.43 11.65 1.23 29.75 13.59 8.02 67.71 
• Kolmogorov-Smirnov two-sample test as outlined in Materials a"d Methods. Plait! ,,,,,,,bers, absent or minimal shift; italics, slight upward shift, and italics ill parentheses, slight 
downward shift; boMface, marked upward shift and boldface in parentheses, marked downward shift. All italics and bold """,bers > 99.9% confidence level (a = 0.001). 
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cell line also had detectable type I IL-IR, similar to the MM-RU cell 
line; however, only the MM-RU cell line responded dramatically to 
the IL-1a. Likewise, the presence or quantity of type II IL-1R did 
not correlate with a motogenic response to the IL-la. Indeed, the 
type II IL-1R was expressed abundantly in the RPM-EP cells (two 
orders of magnitude more than nearly all other receptors on all the 
other cell lines), yet this cell line did not respond to IL-1a, com-
pared to the MM-RU cell line, which expressed relatively small 
amounts of type II IL-1 R. These findings underscore the difficulty 
in correlating expression of these cytokine receptors with a particu-
lar response. Both IL-1 receptor types belong to the Ig superfamily 
and have a large cytoplasmic domain, presumably involved in signal 
transduction. The abundant expression of the type IIIL-1R in the 
RPM-EP cell line and the lack of motogenic response are consistent 
with other investigators reporting in some cell lines that the type II 
IL-1 R is not necessarily coupled to signal transduction [39]. The 
data also suggest that these receptors do not playa significant role in 
signalling proliferation because the expression of the receptors does 
not correlate with the proliferation rates previously published [24]. 
Indeed, addition ofIL-1a did not enhance the proliferation rate in 
our cell lines and, in any case, PM-WK, which has no detectable 
types I or II IL-1R, has a high proliferation rate. 
Similar arguments can be made with regard to attempts at corre-
lating the expression of TNF receptors to enhanced migration in 
response to TNF-a. There are at least two TNF receptors [1B]. Both 
the p60 (55-60 kDa) and pBO TNF-R (75-BO kDa) have been 
identified on normal and malignant cell lines [1B-21] and have a 
cytoplasmic domain that is presumably involved in signal transduc-
tion. Although the MM-RU cell line appears to express slightly 
more p60 and pBO TNF-R than the other cell lines, the number of 
cell lines are too few to make definitive distinct correlations with 
regard to expression and enhanced migration. Similar to the two 
IL-1Rs, TNF receptors have been reported in some cells to have 
signal transduction mediated via the p60 TNF-R and not the pBO 
TNF-R [21,40]. However, other investigators have collected evi-
dence that the pBO TNF-R can also be involved in signal transduc-
tion [1B,41]. It is remarkable how TNF-a, which is known to be 
toxic for a number of tumor cell lines [30], is able to induce an 
acceleration of the cell migration rate on FN. Furthermore, this 
cytokine had no deleterious effect on cell proliferation of the cell 
lines tested. 
The lack of a motogenic effect of IL-1a or TNF-a on laminin-
and dBSA-coated substrate indicated a specificity of this behavior 
for FN. We therefore analyzed the expression of integrin receptors 
on these cell lines to gain insight into whether the motogenic effects 
observed might accompany shifts in integrins known to bind FN. 
Our results suggest that IL-1a and TNF-a induce wide differential 
responses in human melanoma cell lines, indicating another level of 
complexity to the pleiotrophic responses of melanoma cells; 
whereas one line showed a number of distinct downward shifts in a 
subunits in response to one or the other cytokine, two cell lines 
showed a distinct downward shift in response to IL-a only. In 
contrast, the cell line exhibiting the most significant motogenic 
response to both IL-1a and TNF-a showed the greatest shifts in the 
a 4 and as integrins induced by both of these cytokines. 
Taken together, these findings indicate that IL-1a or TNF-a, 
coupled with expression of their receptors, can induce an upregula-
tion of a4PI and asPl integrins. These integrins are known to bind 
with high affinity to the fibronectin molecule and to participate in 
cell motility on FN [42,43]. The inhibition of the enhanced cyto-
kine-induced motility by function-blocking MoAbs against the a 4 
and as integrin subunits indicates that the IL-1a- and TNF-a-
induced effects on the motility of melanoma cells on FN may be 
related, in part, to upregulation of the FN receptors. The data also 
suggest that expression of IL-1 or TNF receptors is not necessarily 
coupled to signal transduction mechanisms that induce a motogenic 
response. Precisely how the link between cytokine receptors and 
increased motility is made is unknown, but it is likely dependent on 
a cascade of signals involving contractile elements of the cytoskele-
ton to engage with integrins binding to FN. Further investigation 
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into these cytokine-induced motogenic effects on melanoma cells 
may help in understanding the molecular mechanisms of melanoma 
cell dissemination. 
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